Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neuroblastoma 1Ganglioneuroblastoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 17Radiotherapy 13Paclitaxel 13Cisplatin 9Vinorelbine 5Pemetrexed 5Gemcitabine 5Docetaxel 5Mastectomy, Segmental 4Gefitinib 4Bevacizumab 4Taxes 3Radiation 3Etoposide 3ceritinib 2shark cartilage extract 1pembrolizumab 1pegfilgrastim 1lorlatinib 1lazertinib 1efaproxiral 1Vindesine 1Vinblastine 1Tirapazamine 1Therapeutics 1Thalidomide 1Surgical Procedures, Operative 1Nivolumab 1Neoadjuvant Therapy 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma of Lung × lorlatinib × Clear all
NCT06858410 2025-03-05

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Guangdong Association of Clinical Trials

Phase 3 Not yet recruiting
36 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡